“There is a low chance for olmesartan therapies to cause trouble in Korea”
The Korean Society of Hypertension turned in “Reply to the French Olmesartan Issue” to the Ministry of Food and Drug Safety(MFDS) on April 19.
The reply is a follow-up of the MFDS’s request for the “Opinions and Data about Necessity of Domestic Measures and Substitute Therapies regarding the Fr...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
